title: The effect of an abuse-deterrent opioid formulation (OxyContin) on opioid abuse-related outcomes in the postmarketing setting.
abstract: An extended-release opioid analgesic (OxyContin, OC) was reformulated with abuse-deterrent properties to deter abuse. This report examines changes in abuse through oral and nonoral routes, doctor-shopping, and fatalities in 10 studies 3.5 years after reformulation. Changes in OC abuse from 1 year before to 3 years after OC reformulation were calculated, adjusted for prescription changes. Abuse of OC decreased 48% in national poison center surveillance systems, decreased 32% in a national drug treatment system, and decreased 27% among individuals prescribed OC in claims databases. Doctor-shopping for OC decreased 50%. Overdose fatalities reported to the manufacturer decreased 65%. Abuse of other opioids without abuse-deterrent properties decreased 2 years later than OC and with less magnitude, suggesting OC decreases were not due to broader opioid interventions. Consistent with the formulation, decreases were larger for nonoral than oral abuse. Abuse-deterrent opioids may mitigate abuse and overdose risks among chronic pain patients.
authors.affiliation: Department of Risk Management and Epidemiology, Purdue Pharma L.P., Stamford, Connecticut, USA.|Adjunct, Epidemiology Department, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
authors.forename: P M
authors.initials: PM
authors.lastname: Coplan
authors.affiliation: Department of Risk Management and Epidemiology, Purdue Pharma L.P., Stamford, Connecticut, USA.|Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
authors.forename: H D
authors.initials: HD
authors.lastname: Chilcoat
authors.affiliation: Inflexxion Inc., Newton, Massachusetts, USA.
authors.forename: S F
authors.initials: SF
authors.lastname: Butler
authors.affiliation: DL Global Partners Inc, Toronto, Canada.|Pharmacology and Toxicology, Medicine and Psychiatry, University of Toronto, Toronto, Canada.
authors.forename: E M
authors.initials: EM
authors.lastname: Sellers
authors.affiliation: Department of Risk Management and Epidemiology, Purdue Pharma L.P., Stamford, Connecticut, USA.
authors.forename: A
authors.initials: A
authors.lastname: Kadakia
authors.affiliation: Department of Risk Management and Epidemiology, Purdue Pharma L.P., Stamford, Connecticut, USA.
authors.forename: V
authors.initials: V
authors.lastname: Harikrishnan
authors.affiliation: Department of Health Policy, Purdue Pharma L.P., Stamford, Connecticut, USA.|Department of Public Health & Community Medicine, School of Medicine, Tufts University, Boston, Massachusetts, USA.
authors.forename: J D
authors.initials: JD
authors.lastname: Haddox
authors.affiliation: Rocky Mountain Poison & Drug Center, Denver, Colorado, USA.|Surgery and Medicine, University of Colorado Health Sciences Center, Denver, Colorado, USA.
authors.forename: R C
authors.initials: RC
authors.lastname: Dart
mesh_terms: D000701:Analgesics, Opioid / Q000008:administration & dosage*; D002626:Chemistry, Pharmaceutical / Q000379:methods*; D004333:Drug Administration Routes; D006801:Humans; D009293:Opioid-Related Disorders / Q000453:epidemiology* / Q000401:mortality; D010098:Oxycodone / Q000008:administration & dosage*; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data; D064226:Prescription Drug Diversion / Q000706:statistics & numerical data; D063487:Prescription Drug Misuse / Q000706:statistics & numerical data; D011358:Product Surveillance, Postmarketing; D012111:Residence Characteristics; D014481:United States / Q000453:epidemiology
chemical_list: D000701:Analgesics, Opioid; D010098:Oxycodone